[{"address1": "500 Unicorn Park Drive", "address2": "Suite 303", "city": "Woburn", "state": "MA", "zip": "01801", "country": "United States", "phone": "781 222 9600", "website": "https://www.replimune.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.", "fullTimeEmployees": 331, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip  Astley-Sparke F.S.A.", "age": 52, "title": "Executive Chairman", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 960520, "exercisedValue": 0, "unexercisedValue": 435967}, {"maxAge": 1, "name": "Mr. Paul  Bullock", "title": "Chief Manufacturing Officer & Framingham Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 10.04, "open": 9.87, "dayLow": 9.76, "dayHigh": 10.5, "regularMarketPreviousClose": 10.04, "regularMarketOpen": 9.87, "regularMarketDayLow": 9.76, "regularMarketDayHigh": 10.5, "beta": 1.251, "forwardPE": -3.8104088, "volume": 497184, "regularMarketVolume": 497184, "averageVolume": 1184145, "averageVolume10days": 714110, "averageDailyVolume10Day": 714110, "bid": 10.22, "ask": 10.28, "bidSize": 100, "askSize": 300, "marketCap": 700294336, "fiftyTwoWeekLow": 4.92, "fiftyTwoWeekHigh": 21.63, "fiftyDayAverage": 7.9235, "twoHundredDayAverage": 8.842325, "currency": "USD", "enterpriseValue": 284705824, "floatShares": 41376585, "sharesOutstanding": 68321400, "sharesShort": 5972920, "sharesShortPriorMonth": 9390972, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0874, "heldPercentInsiders": 0.048299998, "heldPercentInstitutions": 0.90713, "shortRatio": 4.12, "shortPercentOfFloat": 0.1267, "bookValue": 6.098, "priceToBook": 1.680879, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -215794000, "trailingEps": -3.24, "forwardEps": -2.69, "enterpriseToEbitda": -1.237, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "REPL", "underlyingSymbol": "REPL", "shortName": "Replimune Group, Inc.", "longName": "Replimune Group, Inc.", "firstTradeDateEpochUtc": 1532093400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea19e92f-8d00-3fa8-9834-419bd79af5bf", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.25, "targetHighPrice": 17.0, "targetLowPrice": 10.0, "targetMeanPrice": 14.0, "targetMedianPrice": 13.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 420668000, "totalCashPerShare": 6.85, "ebitda": -230198000, "totalDebt": 75869000, "quickRatio": 10.525, "currentRatio": 10.724, "debtToEquity": 20.258, "returnOnAssets": -0.2566, "returnOnEquity": -0.46417, "freeCashflow": -115868624, "operatingCashflow": -185467008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]